Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

ImpediMed enrols first patient in chronic heart failure trial

ImpediMed (ASX:IPD) has enrolled the first patient in its initial chronic heart failure (CHF) trial using the company’s “SOZO” device.

Updater Inc to reveal material results

Updater Inc (ASX:IPD) has been granted a trading halt in its CHESS Depositary Interests by the ASX, with its shares placed in pre-open.

ImpediMed begins lymphoedema study using its health device

ImpediMed (ASX:IPD) has commenced enrolment in the first planned clinical study of its “SOZO” device for lymphoedema, a condition that causes swelling in the body's tissues.

ImpediMed Ltd and Mayo Clinic to progress body fluid monitoring technology

ImpediMed Ltd (ASX:IPD) is a leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies.

ImpediMed Limited Release: Vanderbilt University To Begin Testing Next Generation Device

2016-07-18 devicespace
BRISBANE, Australia and CARLSBAD, Calif., July 18, 2016 /PRNewswire/ -- ImpediMed Limited (ASX:IPD) announces that it is partnering with Vanderbilt University for a series of patient and clinician human factors testing for the company's next generation technology platform. Testing is expected to conclude by end of September 2016.

ImpediMed Limited Release: Medicare Proposes New Reimbursement Rates, L-Dex Increases

2016-07-12 devicespace
BRISBANE, Australia and CARLSBAD, Calif., July 12, 2016 /PRNewswire/ -- ImpediMed Limited (ASX:IPD) is pleased to announce today the Centers for Medicare and Medicaid Services (CMS) has published the proposed outpatient payment rates for CY2017.  This includes code 93702 for the company's L-Dex® procedure for the assessment of lymphedema.  

Becoming a substantial holder


Appendix 3B


Change in substantial holding


Appendix 3B


Notice under section 708A(5)(e)


ImpediMed completes A$75 million Private Placement

2016-03-22 prnewswire
CARLSBAD, Calif., March 22, 2016 /PRNewswire/ -- ImpediMed Limited (ASX: IPD), a global provider of medical technology to measure, monitor and manage fluid status in patients, announced the completion of its recent capital raising activity, raising a total of A$75.1 million before costs.